Look back at pharma news in the week to February 19, 2021 February 22, 2021

21 February 2021

By Barbara Obstoj-Cardwell. Editor

Notable research news last week included Swiss pharma giant Roche releasing new Phase III data on its diabetic macular degeneration (DME) candidate faricimab. On the disappointing side, bluebird bio reported that its rare diseases therapies LentiGlobin and Zynteglo have been connected to a case of acute myeloid leukemia (AML). On the deal-making front, Nektar Therapies had a busy day last Thursday, when it announced a research financing deal with SFJ Pharma on its bempegaldesleukin and also a research collaboration with Merck & Co. Elsewhere, Astellas and Seagen have filed for US Food and Drug Administration approval for their metastatic urothelial cancer drug Padcev.

Faricimab’s full data doesn’t make it a category killer – on par with Eylea

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK